Clinical trials: Chronic Obstructive Pulmonary
GVHD, Chronic
TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD))
1. Phase Ib study stage: Primary objective: To evaluate the efficacy and safety Secondary objectives: To evaluate the population pharmacokinetic characteristics 2.
- Trial name
- NCT06169722
- Testing
- TDI01 suspension
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
Chronic Obstructive Pulmonary Disease
Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations
This study is designed to assess the effect of once-daily QVA149 on COPD exacerbations in patients with severe to very severe COPD.
- Trial name
- SPARK (NCT01120691)
- Testing
- QVA149, NVA237, tiotropium
- Where
- 342 sites in United States, Argentina and 26 more
- Volunteers
- 2,224 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Juvenile Idiopathic Arthritis (SJIA)
ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab
The purpose of this study was to evaluate the efficacy observed with canakinumab dose reduction in a subgroup of patients in the extension study CACZ885G2301E1.
- Trial name
- ß-SPECIFIC 4 (NCT02296424)
- Testing
- ACZ885 150 mg (Canakinumab)
- Where
- 50 sites in United States, Austria and 14 more
- Volunteers
- 182 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza
The aim of the study is to assess the safety of inhaled SNG001 and the ability of inhaled SNG001 to 'switch on' the cells' anti-viral defences in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT03570359
- Testing
- Interferon Beta-1A
- Where
- 16 sites in United Kingdom
- Volunteers
- 122 people
- Sponsor
- Synairgen Research Ltd.
Chronic Obstructive Pulmonary Disease - COPD
Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Male Japanese Subjects
AZD8871 is a new chemical entity possessing long-acting dual-pharmacology (muscarinic receptor antagonist and β2 adrenoceptor agonist [MABA]) in a single molecule.
- Trial name
- NCT03159442
- Testing
- AZD8871
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Graft vs Host Disease
Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant
This open-label, single-arm, Phase II multi-center study enrolled 46 participants and investigated the activity, pharmacokinetics and safety of ruxolitinib added to the subject's immunosuppressive regimen among infants, children…
- Trial name
- REACH 5 (NCT03774082)
- Testing
- INC424
- Where
- 21 sites in Brazil, Canada and 12 more
- Volunteers
- 46 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease, Lung Disease
AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)
The purpose of the study is to investigate the tolerability and safety of AZD2423 in Patients with chronic obstructive pulmonary disease.
- Trial name
- NCT01215279
- Testing
- AZD2423
- Where
- 6 sites in Bulgaria, Slovakia
- Volunteers
- 63 people
- Sponsor
- AstraZeneca
Respiratory Tract Diseases, Abnormal Mucus Secretions
A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions
This is a phase 3, multicenter, randomized, rater- and patient-blind, placebo- and active-controlled, 3-arm parallel group clinical trial.
- Trial name
- NCT03843541
- Testing
- N-acetylcysteine (NAC) 600 mg, Ambroxol hydrochloride 30 mg
- Where
- 32 sites in China
- Volunteers
- 333 people
- Sponsor
- Zambon SpA
Myelogenous Leukemia, Chronic, Neoplasms, Myelogenous Leukemia, Acute
An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies
This open-label, extension study is designed to provide continuing treatment with RO5045337 to participants who have completed parent studies NO21279 (NCT00623870), NO21280 (NCT00559533), NP25299 (NCT01164033), NP28021…
- Trial name
- NCT01677780
- Testing
- RO5045337
- Where
- 5 sites in United States, Canada and 1 more
- Volunteers
- 11 people
- Sponsor
- Hoffmann-La Roche
COPD
Acute Bronchodilator Effect of Inhaled Albuterol Sulfate and Ipratropium Bromide in Patients With Stable COPD
The purpose of this study is to demonstrate the pharmacodynamic bioequivalence of the test product to the reference product as measured by increases in FEV1.
- Trial name
- NCT03480997
- Testing
- Albuterol Sulfate and Ipratropium Bromide, Albuterol Sulfate
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Pneuma Respiratory, Inc
Chronic Obstructive Pulmonary Disease
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of RV1729 for 28 Days in Patients With COPD
RV1729 is a new medicine being developed for the potential treatment of asthma and smoking related lung disease (also known as chronic obstructive pulmonary disease - COPD).
- Trial name
- NCT02140346
- Testing
- RV1729 28 day repeat dose
- Where
- 2 sites in United Kingdom
- Volunteers
- 48 people
- Sponsor
- Respivert Ltd
Chronic Obstructive Pulmonary Disease
Respiratory Physiology Under High Flow Therapy
The aim of this study is to gain knowledge about effects of high flow transnasal insufflation on various breathing parameters like intratracheal pressure conditions, CO2 elimination, breathing frequency and tidal volume.
- Trial name
- NCT01509703
- Testing
- High flow therapy
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Institut für Pneumologie Hagen Ambrock eV
Chronic Obstructive Pulmonary Disease
An Exploratory Study, to Assess the Effect of Repeat-dose Inhaled Indacaterol Maleate (300 μg) on Dynamic and Static Lung Hyperinflation, Subjective Breathlessness and Health Status in Patients With Chronic Obstructive Pulmonary Disease(COPD)
This study evaluated the effect of QAB149 on dynamic and static hyperinflation, breathlessness, and health status in COPD patients
- Trial name
- NCT00636961
- Testing
- Indacaterol 300μg
- Where
- 3 sites in Germany
- Volunteers
- 27 people
- Sponsor
- Novartis
Pulmonary Disease, Chronic Obstructive
A Single Dose Study to Determine the Excretion, Balance and Metabolic Disposition of Radiolabelled GW642444.
The purpose of this study is to characterise the metabolic disposition of radiolabelled GW642444 when administered orally.
- Trial name
- NCT01286831
- Testing
- [14C]GW642444
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
Safety and Tolerability of Inhaled CHF 6001 in Healthy Volunteers (HV)
This study is designed to investigate the safety, tolerability and pharmacokinetics of inhaled CHF 6001 after single and multiple doses in healthy volunteers.
- Trial name
- NCT01703052
- Where
- United Kingdom
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
Vector Efficacy Cross-Over Pilot Study
The study evaluates the safety and efficacy of the modified Bi-level positive airway pressure (BiPAP) A40 with Vector Algorithm to treat Chronic Obstructive Pulmonary Disease (COPD) patients with excessive carbon dioxide in their…
- Trial name
- NCT04263532
- Testing
- Modified BiPAP A40 with Vector Algorithm (Vector), Modified BiPAP A40 with Standard of Care Settings
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema
Longitudinal Follow up to Assess Biomarkers Predictive of Emphysema Progression in Patients With COPD (Chronic Obstructive Pulmonary Disease)
The study will include 60 healthy subjects (ex-smoker without any airflow limitation), 125 COPD GOLD (global initiative for chronic obstructive lung disease) I , 125 COPD GOLD II, 125 COPD GOLD III and up to 20 patients with COPD…
- Trial name
- NCT02719184
- Where
- 51 sites in United States, Belgium and 10 more
- Volunteers
- 463 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to compare the efficacy and safety/tolerability of indacaterol and glycopyrronium (QVA149) (fixed-dose combination) with fluticasone/salmeterol over a 26-week period in patients with moderate to…
- Trial name
- ILLUMINATE (NCT01315249)
- Testing
- indacaterol and glycopyrronium (QVA149), fluticasone/salmeterol
- Where
- 93 sites in Belgium, Czechia and 7 more
- Volunteers
- 523 people
- Sponsor
- Novartis Pharmaceuticals
COPD
A Study to Evaluate Safety and Efficacy of BOTOX in Adults With Moderate COPD
The aim of this clinical trial to determine the safety and effectiveness of treating the COPD symptoms with subcutaneous BOTOX injections in participants with moderate COPD.
- Trial name
- NCT06003049
- Testing
- OnabotulinumtoxinA
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- RMW Testing
COPD
Evaluation of COPD Co-Pilot
The purpose of undertaking this study is to examine the use of COPD Co-PilotTM, a COPD disease management program manufactured and operated by HGE Health Care Solutions, LLC, in COPD patients outside of the geographic base of…
- Trial name
- NCT03018847
- Testing
- COPD Co-Pilot
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- HGE Health Care Solutions, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.